These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
24. Antioxidants for the treatment of mild cognitive impairment. Mecocci P; Mariani E; Cornacchiola V; Polidori MC Neurol Res; 2004 Jul; 26(5):598-602. PubMed ID: 15265281 [TBL] [Abstract][Full Text] [Related]
25. The oxidative stress hypothesis in Alzheimer's disease. Padurariu M; Ciobica A; Lefter R; Serban IL; Stefanescu C; Chirita R Psychiatr Danub; 2013 Dec; 25(4):401-9. PubMed ID: 24247053 [TBL] [Abstract][Full Text] [Related]
26. Antioxidant approaches for the treatment of Alzheimer's disease. Lee HP; Zhu X; Casadesus G; Castellani RJ; Nunomura A; Smith MA; Lee HG; Perry G Expert Rev Neurother; 2010 Jul; 10(7):1201-8. PubMed ID: 20586698 [TBL] [Abstract][Full Text] [Related]
27. miRNAs as biofluid markers for diagnostics of Alzheimer's disease: recent status and perspectives. Kosikova N; Cente M; Cigankova V; Koson P; Filipcik P Gen Physiol Biophys; 2018 Sep; 37(5):495-514. PubMed ID: 30307401 [TBL] [Abstract][Full Text] [Related]
28. Simultaneous activation of Nrf2 and elevation of antioxidant compounds for reducing oxidative stress and chronic inflammation in human Alzheimer's disease. Prasad KN Mech Ageing Dev; 2016 Jan; 153():41-7. PubMed ID: 26811881 [TBL] [Abstract][Full Text] [Related]
29. Serum levels of vitamin E forms and risk of cognitive impairment in a Finnish cohort of older adults. Mangialasche F; Solomon A; Kåreholt I; Hooshmand B; Cecchetti R; Fratiglioni L; Soininen H; Laatikainen T; Mecocci P; Kivipelto M Exp Gerontol; 2013 Dec; 48(12):1428-35. PubMed ID: 24113154 [TBL] [Abstract][Full Text] [Related]
30. Development of Alzheimer-disease neuroimaging-biomarkers using mouse models with amyloid-precursor protein-transgene expression. Teipel SJ; Buchert R; Thome J; Hampel H; Pahnke J Prog Neurobiol; 2011 Dec; 95(4):547-56. PubMed ID: 21601614 [TBL] [Abstract][Full Text] [Related]
31. Searching for the role and the most suitable biomarkers of oxidative stress in Alzheimer's disease and in other neurodegenerative diseases. Migliore L; Fontana I; Colognato R; Coppede F; Siciliano G; Murri L Neurobiol Aging; 2005 May; 26(5):587-95. PubMed ID: 15708433 [TBL] [Abstract][Full Text] [Related]
32. The emerging role of glutathione in Alzheimer's disease. Saharan S; Mandal PK J Alzheimers Dis; 2014; 40(3):519-29. PubMed ID: 24496077 [TBL] [Abstract][Full Text] [Related]
33. Biomarkers for preclinical Alzheimer's disease. Tan CC; Yu JT; Tan L J Alzheimers Dis; 2014; 42(4):1051-69. PubMed ID: 25024325 [TBL] [Abstract][Full Text] [Related]
34. Lipids' peroxidation markers in Alzheimer's disease and vascular dementia. Gustaw-Rothenberg K; Kowalczuk K; Stryjecka-Zimmer M Geriatr Gerontol Int; 2010 Apr; 10(2):161-6. PubMed ID: 20446930 [TBL] [Abstract][Full Text] [Related]
35. Changes of some oxidative stress markers in the serum of patients with mild cognitive impairment and Alzheimer's disease. Padurariu M; Ciobica A; Hritcu L; Stoica B; Bild W; Stefanescu C Neurosci Lett; 2010 Jan; 469(1):6-10. PubMed ID: 19914330 [TBL] [Abstract][Full Text] [Related]
36. Proteomic identification of brain proteins in the canine model of human aging following a long-term treatment with antioxidants and a program of behavioral enrichment: relevance to Alzheimer's disease. Opii WO; Joshi G; Head E; Milgram NW; Muggenburg BA; Klein JB; Pierce WM; Cotman CW; Butterfield DA Neurobiol Aging; 2008 Jan; 29(1):51-70. PubMed ID: 17055614 [TBL] [Abstract][Full Text] [Related]